Matarin Capital Management’s PDL BioPharma, Inc. PDLI Stock Holding History

Matarin Capital Management’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-927,289	Closed	-$2.17M	–	328
2018 Q2	$2.17M	Sell	927,289 -199,352	-18%	-$557K	0.16%	164
2018 Q1	$3.31M	Buy	1,126,641 +88,469	+9%	+$241K	0.25%	143
2017 Q4	$2.84M	Buy	1,038,172 +996,002	+2,362%	+$3.06M	0.22%	150
2017 Q3	$143K	Buy	+42,170	New	+$117K	0.01%	285
2014 Q1	–	Sell	-15,753	Closed	-$133K	–	184
2013 Q4	$133K	Buy	+15,753	New	+$133K	0.08%	120

Other funds holding PDLI

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Matarin Capital Management's PDLI Position: Q3 2018 in Review

Matarin Capital Management sold out of PDL BioPharma, Inc. (PDLI) in Q3 2018, closing a stake of 927,289 shares — an estimated $2.17M sold.

Matarin Capital Management first reported a position in PDLI in Q4 2013 and held it in 5 quarters. The position peaked at $3.31M in Q1 2018. 152 funds tracked by Wall St. Rank hold PDLI as of Q3 2018.

Matarin Capital Management reported no remaining PDL BioPharma, Inc. position as of Q3 2018 after selling out during the quarter.
Matarin Capital Management sold 927,289 PDL BioPharma, Inc. shares in Q3 2018, an estimated $2.17M.
Matarin Capital Management first reported a position in PDL BioPharma, Inc. in Q4 2013 and held it in 5 quarters.
Matarin Capital Management's PDL BioPharma, Inc. position peaked at $3.31M in Q1 2018.
152 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q3 2018.

Based on Matarin Capital Management's 13F filing for Q3 2018, filed 14 Nov 2018.